ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05665-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Jean-Jacques Kiladjian und 40 weiteren Autor:innen. Beteiligte Einrichtung: CIC 1427, Inserm, Université Paris Cité, 75010, Paris, France. jean-jacques.kiladjian@aphp.fr. Hauptthemen laut MEDLINE: Interferon alpha-2, Interferon-alpha, Polyethylene Glycols, Recombinant Proteins. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AOP Health.
Abstract (Originalsprache)
Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). Current ET treatments aim to normalize hematological parameters and reduce the thrombotic risk, but they do not modify the natural history of the disease and hence, have no impact on disease progression. Ropeginterferon alfa-2b (trade name BESREMi®), a novel, monopegylated interferon alfa-2b with an extended administration interval, has demonstrated a robust and sustained efficacy in polycythemia vera (PV) patients. Given the similarities in disease pathophysiology and treatment goals, ropeginterferon alfa-2b holds promise as a treatment option for ET. The ROP-ET trial is a prospective, multicenter, single-arm phase III study that includes patients with ET who are intolerant or resistant to, and/or are ineligible for current therapies, such as hydroxyurea (HU), anagrelide (ANA), busulfan (BUS) and pipobroman, leaving these patients with limited treatment options. The primary endpoint is a composite response of hematologic parameters and disease-related symptoms, according to modified European LeukemiaNet (ELN) criteria. Secondary endpoints include improvements in symptoms and quality of life, molecular response and the safety profile of ropeginterferon alfa-2b. Over a 3-year period the trial assesses longer term outcomes, particularly the effects on allele burden and clinical outcomes, such as disease-related symptoms, vascular events and disease progression. No prospective clinical trial data exist for ropeginterferon alfa-2b in the planned ET study population and this study will provide new findings that may contribute to advancing the treatment landscape for ET patients with limited alternatives. Trial registration EU Clinical Trials Register; EudraCT, 2023-505160-12-00; Registered on October 30, 2023.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CIC 1427, Inserm, Université Paris Cité, 75010, Paris, France. jean-jacques.kiladjian@aphp.fr.
- Centre d'Investigations Cliniques, AP-HP, Hôpital Saint-Louis, Paris, 75010, France. jean-jacques.kiladjian@aphp.fr.
- Morales Meseguer University General Hospital, Regional Center of Blood Donation. CIBERER. UCAM. IMIB-Murcia, Murcia, Spain.
- University Hospital Halle (Saale), Krukenberg Cancer Center Halle, Halle, Germany.
- Department of Hematology, Hospital Clínic of Barcelona, Barcelona, Spain.
- University Hospital City of Health and Science of Turin - Hospital Molinette, Complex Structure of Hematology, Torino, Italy.
Förderung
- AOP Health
Zitieren
APA
Kiladjian, J. J., Marin, F. F., Al-Ali, H. K., Alvarez-Larrán, A., Beggiato, E., Bieniaszewska, M., Breccia, M., Buxhofer-Ausch, V., Cerna, O., Crisan, A. M., Danaila, C. D., De Stefano, V., Döhner, K., Empson, V., Gora-Tybor, J., Griesshammer, M., Grosicki, S., Guglielmelli, P., García-Gutierrez, V., …, & Klade, C. (2024). ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Annals of Hematology. https://doi.org/10.1007/s00277-024-05665-4
Vancouver
Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larrán A, Beggiato E, Bieniaszewska M, et al. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Annals of Hematology. 2024. doi:10.1007/s00277-024-05665-4
BibTeX
@article{Kiladjian2024,
author = {Kiladjian, Jean-Jacques and Marin, Francisca Ferrer and Al-Ali, Haifa Kathrin and Alvarez-Larrán, Alberto and Beggiato, Eloise and Bieniaszewska, Maria and Breccia, Massimo and Buxhofer-Ausch, Veronika and Cerna, Olga and Crisan, Ana-Manuela and Danaila, Catalin Doru and De Stefano, Valerio and Döhner, Konstanze and Empson, Victoria and Gora-Tybor, Joanna and Griesshammer, Martin and Grosicki, Sebastian and Guglielmelli, Paola and García-Gutierrez, Valentin and Heidel, Florian H and Illés, Arpád and Tomuleasa, Ciprian and James, Chloe and Koschmieder, Steffen and Krauth, Maria-Theresa and Krejcy, Kurt and Lazaroiu, Mihaela-Cornelia and Mayer, Jiri and Nagy, Zsolt György and Nicolini, Franck-Emmanuel and Palandri, Francesca and Pappa, Vassiliki and Reiter, Andreas Johannes and Sacha, Tomasz and Schlager, Stefanie and Schmidt, Stefan and Terpos, Evangelos and Unger, Martin and Wölfler, Albert and Cirici, Blanca Xicoy and Klade, Christoph},
title = {ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05665-4}
}
EUVIMED